Evidence map›Paper›PMID 33738668›Full record

ArticleInvestigational new drugs2021

Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study.

Katrina S Pedersen, Patrick M Grierson, Joel Picus, A Craig Lockhart, Bruce J Roth, Jingxia Liu, Ashley Morton, Emily Chan, Jesse Huffman, Chris Liang and 2 more

Abstract readClinical Trial, Phase I
PubMed Publisher
In one paragraph

Article in Investigational new drugs, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 32 citations in OpenAlex.

  1. Review
  2. CombiningFrontiers in pharmacology · 2026
    Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Katrina S PedersenDivision of Oncology, Washington University, St. Louis, MO, USA.ORCID http://orcid.org/0000-0003-2793-6901
Patrick M GriersonDivision of Oncology, Washington University, St. Louis, MO, USA.
Joel PicusDivision of Oncology, Washington University, St. Louis, MO, USA.
A Craig LockhartDivision of Medical Oncology, University of Miami, Miami, FL, USA.
Bruce J RothDivision of Oncology, Washington University, St. Louis, MO, USA.
Jingxia LiuDivision of Public Health Sciences, Washington University, St. Louis, MO, USA.
Ashley MortonDivision of Oncology, Washington University, St. Louis, MO, USA.
Emily ChanDivision of Oncology, Vanderbilt University, Nashville, TN, USA.
Jesse HuffmanDivision of Oncology, Washington University, St. Louis, MO, USA.
Chris LiangXcovery, Palm Beach Gardens, FL, USA.
Andrea Wang-GillamDivision of Oncology, Washington University, St. Louis, MO, USA.
Benjamin TanDivision of Oncology, Washington University, St. Louis, MO, USA. btan@wustl.edu.
Washington University in St. Louis · USUniversity of Miami · USVanderbilt University · USXcovery (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Anti-vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors (TKI) combined with mTOR inhibitors, like everolimus, result in significant responses and prolonged progression-free survival (PFS) among patients with renal cell carcinoma (RCC) [1]. However, everolimus doses >5 mg are often not tolerated when combined with other TKIs

Indexed as

AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsDose-Response Relationship, DrugEverolimusFemaleHumansIndolesMaleMaximum Tolerated DoseMiddle AgedMTOR InhibitorsNeoplasmsProtein Kinase InhibitorsPyrrolesEverolimusIndolesMTOR InhibitorsProtein Kinase InhibitorsPyrrolesPyrrolidinesReceptors, Colony-Stimulating FactorReceptors, Platelet-Derived Growth FactorReceptors, Vascular Endothelial Growth FactorvorolanibEverolimusNeuroendocrine carcinomaPhase 1Renal cell carcinomaVorolanibX-82

Identifiers

PMID33738668
OpenAlexW3137947413

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.